论文部分内容阅读
近年来IL-13受体IL-13Rα2的研究已经成为一个新兴热点,IL-13Rα2在许多肿瘤细胞细胞表面存在特异性高表达,而在正常组织中不表达或表达量很低,通过IL-13Rα2介导的毒素融合蛋白靶向治疗肿瘤也已成为肿瘤诊断和免疫治疗研究中的重要方面。随着对IL-13Rα2结构和功能及其与肿瘤关系研究的不断深入,将为肿瘤的靶向治疗提供新的思路,为肿瘤的临床治疗提供新的理论依据。对IL-13Rα2在不同肿瘤中的表达及IL-13和不同毒素融合得到的毒素融合蛋白在细胞和动物体内等不同水平上对肿瘤治疗的作用做出了相应概括,并对通过IL-13Rα2介导的毒素融合蛋白治疗肿瘤机理的研究以及融合蛋白方法改进及其它相关治疗方法等方面作出综述。
In recent years, the research of IL-13 receptor IL-13Rα2 has become a new hot spot. IL-13Rα2 is highly expressed on the surface of many tumor cells, but not expressed in normal tissues or expressed very low. Through IL-13Rα2 Targeted toxin fusion proteins targeted to treat tumors have also become an important aspect in the study of tumor diagnosis and immunotherapy. With the further research on the structure and function of IL-13Rα2 and its relationship with tumor, it will provide new ideas for the targeted therapy of tumor and provide a new theoretical basis for the clinical treatment of tumor. The expression of IL-13Rα2 in different tumors and the role of the toxin fusion protein obtained by the fusion of IL-13 and different toxins on tumor therapy at different levels in cells and animals were summarized. The effects of IL-13Rα2 mediated by IL-13Rα2 Introduction of toxin fusion proteins in the treatment of tumor mechanisms and the improvement of fusion protein methods and other related treatment methods are reviewed.